WATERTOWN, Mass., March 15, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that an abstract supporting the Company's Durasert three-year treatment for posterior segment uveitis has been accepted for a paper presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting being held in Baltimore, MD from May 7-11, 2017.

The abstract accepted for paper presentation is titled, " An Injectable Fluocinolone Acetonide Intravitreal Insert Decreases the Incidence of Recurrence in Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye: 12 Month Results." The data will be presented by Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC, during the session titled, " Emerging Treatments for Uveitis," scheduled for Monday, May 8, 2017 from 9:00am to 9:15am ET.

"ARVO is one of the most important ophthalmology conferences of the year and we are excited that data from our Phase 3 study has been selected," commented Nancy Lurker, President and Chief Executive Officer. "Dr. Jaffe is a recognized authority on posterior segment uveitis and we are looking forward to his presentation to this prestigious audience."

About Posterior Segment Uveitis

Posterior segment uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye, often involving the retina, which is a leading cause of blindness in the developed and developing countries. It afflicts people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness. In the U.S., posterior uveitis affects approximately 175,000 people, resulting in approximately 30,000 cases of blindness and making it the third leading cause of blindness in the U.S.

Patients with posterior uveitis are typically treated with systemic steroids; but, over time, frequently develop serious side effects that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which themselves can have severe side effects including an increased risk of cancer.

If you liked this article you might like

Today's Weak On High Volume Stock: PSivida (PSDV)

Trade-Ideas: PSivida (PSDV) Is Today's Strong On High Relative Volume Stock

Psivida (PSDV) Upgraded From Sell to Hold

Why pSivida (PSDV) Stock Is Soaring in After-Hours Trading Today

3 Stocks Under $10 Moving Higher